Class information for: |
Basic class information |
Class id | #P | Avg. number of references |
Database coverage of references |
---|---|---|---|
6969 | 1422 | 30.1 | 52% |
Hierarchy of classes |
The table includes all classes above and classes immediately below the current class. |
Cluster id | Level | Cluster label | #P |
---|---|---|---|
0 | 4 | BIOCHEMISTRY & MOLECULAR BIOLOGY//CELL BIOLOGY//ONCOLOGY | 4064930 |
210 | 3 | IMMUNOLOGY//JOURNAL OF INTERFERON RESEARCH//NK CELLS | 51916 |
1364 | 2 | JOURNAL OF THE RETICULOENDOTHELIAL SOCIETY//MURAMYL DIPEPTIDE//IMMUNOLOGY | 8243 |
6969 | 1 | MURAMYL DIPEPTIDE//MURAMYL PEPTIDES//PEPTIDOGLYCAN MONOMER | 1422 |
Terms with highest relevance score |
rank | Term | termType | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|---|
1 | MURAMYL DIPEPTIDE | authKW | 477381 | 5% | 34% | 65 |
2 | MURAMYL PEPTIDES | authKW | 349707 | 2% | 53% | 31 |
3 | PEPTIDOGLYCAN MONOMER | authKW | 326595 | 1% | 89% | 17 |
4 | MTP PE | authKW | 173920 | 1% | 90% | 9 |
5 | ROMURTIDE | authKW | 171775 | 1% | 100% | 8 |
6 | ADAMANTYLTRIPEPTIDES | authKW | 128831 | 0% | 100% | 6 |
7 | MURABUTIDE | authKW | 116899 | 0% | 78% | 7 |
8 | LIPOSOMAL MTP PE | authKW | 107359 | 0% | 100% | 5 |
9 | MURAMYL DIPEPTIDE DERIVATIVES | authKW | 107359 | 0% | 100% | 5 |
10 | MURAMYL DIPEPTIDE GLYCOSIDES | authKW | 89464 | 0% | 83% | 5 |
Web of Science journal categories |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | Immunology | 8982 | 38% | 0% | 547 |
2 | Pharmacology & Pharmacy | 1188 | 19% | 0% | 268 |
3 | Infectious Diseases | 763 | 8% | 0% | 108 |
4 | Chemistry, Organic | 690 | 11% | 0% | 162 |
5 | Medicine, Research & Experimental | 623 | 9% | 0% | 126 |
6 | Oncology | 600 | 13% | 0% | 178 |
7 | Chemistry, Medicinal | 460 | 6% | 0% | 86 |
8 | Biochemistry & Molecular Biology | 333 | 17% | 0% | 240 |
9 | Microbiology | 201 | 6% | 0% | 91 |
10 | Chemistry, Applied | 168 | 4% | 0% | 57 |
Address terms |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | IMMUNOL MOL INFECT INFLAMMAT | 76682 | 0% | 71% | 5 |
2 | MOL IMMUNOL INFECT INFLAMMAT | 67096 | 0% | 63% | 5 |
3 | CELL IMMUNOPATHOL BIOTECHNOL | 42944 | 0% | 100% | 2 |
4 | EXPLORATORY S 216 KASHIMA YODOGAWA KU | 42944 | 0% | 100% | 2 |
5 | EXPT DIAGNOST CANC THER Y | 42944 | 0% | 100% | 2 |
6 | IMMUNOL SCI KITA KU | 32205 | 0% | 50% | 3 |
7 | II MECHNIKOV CENT VACCINES SERA | 28628 | 0% | 67% | 2 |
8 | NO AIDS REFERENCE | 28628 | 0% | 67% | 2 |
9 | CANC METASTASIS TREATMENT | 21472 | 0% | 100% | 1 |
10 | CELLULAR IMMUNOPATHOL BIOCHEM | 21472 | 0% | 100% | 1 |
Journals |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | INTERNATIONAL JOURNAL OF IMMUNOPHARMACOLOGY | 38094 | 4% | 3% | 60 |
2 | JOURNAL OF BIOLOGICAL RESPONSE MODIFIERS | 15880 | 1% | 4% | 19 |
3 | INFECTION AND IMMUNITY | 5745 | 6% | 0% | 85 |
4 | CANCER IMMUNOLOGY IMMUNOTHERAPY | 5667 | 2% | 1% | 34 |
5 | BIOTHERAPY | 4659 | 1% | 3% | 8 |
6 | ARZNEIMITTEL-FORSCHUNG/DRUG RESEARCH | 4064 | 2% | 1% | 29 |
7 | BIOORGANICHESKAYA KHIMIYA | 3757 | 2% | 1% | 24 |
8 | INTERNATIONAL JOURNAL OF IMMUNOTHERAPY | 3675 | 1% | 2% | 9 |
9 | CANCER BIOTHERAPY | 3609 | 0% | 4% | 4 |
10 | CARBOHYDRATE RESEARCH | 3431 | 3% | 0% | 47 |
Author Key Words |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
LCSH search | Wikipedia search |
---|---|---|---|---|---|---|---|
1 | MURAMYL DIPEPTIDE | 477381 | 5% | 34% | 65 | Search MURAMYL+DIPEPTIDE | Search MURAMYL+DIPEPTIDE |
2 | MURAMYL PEPTIDES | 349707 | 2% | 53% | 31 | Search MURAMYL+PEPTIDES | Search MURAMYL+PEPTIDES |
3 | PEPTIDOGLYCAN MONOMER | 326595 | 1% | 89% | 17 | Search PEPTIDOGLYCAN+MONOMER | Search PEPTIDOGLYCAN+MONOMER |
4 | MTP PE | 173920 | 1% | 90% | 9 | Search MTP+PE | Search MTP+PE |
5 | ROMURTIDE | 171775 | 1% | 100% | 8 | Search ROMURTIDE | Search ROMURTIDE |
6 | ADAMANTYLTRIPEPTIDES | 128831 | 0% | 100% | 6 | Search ADAMANTYLTRIPEPTIDES | Search ADAMANTYLTRIPEPTIDES |
7 | MURABUTIDE | 116899 | 0% | 78% | 7 | Search MURABUTIDE | Search MURABUTIDE |
8 | LIPOSOMAL MTP PE | 107359 | 0% | 100% | 5 | Search LIPOSOMAL+MTP+PE | Search LIPOSOMAL+MTP+PE |
9 | MURAMYL DIPEPTIDE DERIVATIVES | 107359 | 0% | 100% | 5 | Search MURAMYL+DIPEPTIDE+DERIVATIVES | Search MURAMYL+DIPEPTIDE+DERIVATIVES |
10 | MURAMYL DIPEPTIDE GLYCOSIDES | 89464 | 0% | 83% | 5 | Search MURAMYL+DIPEPTIDE+GLYCOSIDES | Search MURAMYL+DIPEPTIDE+GLYCOSIDES |
Core articles |
The table includes core articles in the class. The following variables is taken into account for the relevance score of an article in a cluster c: (1) Number of references referring to publications in the class. (2) Share of total number of active references referring to publications in the class. (3) Age of the article. New articles get higher score than old articles. (4) Citation rate, normalized to year. |
Rank | Reference | # ref. in cl. |
Shr. of ref. in cl. |
Citations |
---|---|---|---|---|
1 | NARDIN, A , LEFEBVRE, ML , LABROQUERE, K , FAURE, O , ABASTADO, JP , (2006) LIPOSOMAL MURAMYL TRIPEPTIDE PHOSPHATIDYLETHANOLAMINE: TARGETING AND ACTIVATING MACROPHAGES FOR ADJUVANT TREATMENT OF OSTEOSARCOMA.CURRENT CANCER DRUG TARGETS. VOL. 6. ISSUE 2. P. 123-133 | 56 | 76% | 52 |
2 | ADAM, A , LEDERER, E , (1984) MURAMYL PEPTIDES - IMMUNOMODULATORS, SLEEP FACTORS, AND VITAMINS.MEDICINAL RESEARCH REVIEWS. VOL. 4. ISSUE 2. P. 111-152 | 97 | 82% | 196 |
3 | MEYERS, PA , (2009) MURAMYL TRIPEPTIDE (MIFAMURTIDE) FOR THE TREATMENT OF OSTEOSARCOMA.EXPERT REVIEW OF ANTICANCER THERAPY. VOL. 9. ISSUE 8. P. 1035-1049 | 42 | 70% | 43 |
4 | DZIERZBICKA, K , KOLODZIEJCZYK, AM , (2003) MURAMYL PEPTIDES - SYNTHESIS AND BIOLOGICAL ACTIVITY.POLISH JOURNAL OF CHEMISTRY. VOL. 77. ISSUE 4. P. 373-395 | 42 | 82% | 12 |
5 | ANDO, K , MORI, K , CORRADINI, N , REDINI, F , HEYMANN, D , (2011) MIFAMURTIDE FOR THE TREATMENT OF NONMETASTATIC OSTEOSARCOMA.EXPERT OPINION ON PHARMACOTHERAPY. VOL. 12. ISSUE 2. P. 285-292 | 40 | 63% | 21 |
6 | MORI, K , ANDO, K , HEYMANN, D , (2008) LIPOSOMAL MURAMYL TRIPEPTIDE PHOSPHATIDYL ETHANOLAMINE: A SAFE AND EFFECTIVE AGENT AGAINST OSTEOSARCOMA PULMONARY METASTASES.EXPERT REVIEW OF ANTICANCER THERAPY. VOL. 8. ISSUE 2. P. 151-159 | 42 | 64% | 9 |
7 | OREILLY, T , ZAK, O , (1992) ENHANCEMENT OF THE EFFECTIVENESS OF ANTIMICROBIAL THERAPY BY MURAMYL PEPTIDE IMMUNOMODULATORS.CLINICAL INFECTIOUS DISEASES. VOL. 14. ISSUE 5. P. 1100-1109 | 53 | 75% | 25 |
8 | FRKANEC, R , TOMASIC, J , (2008) HIGH PERFORMANCE LIQUID CHROMATOGRAPHY IN ANALYSIS OF COMPOUNDS COMPRISING THE ELEMENTS OF BACTERIAL PEPTIDOGLYCAN STRUCTURE WITH IMMUNOLOGICAL ACTIVITY.JOURNAL OF LIQUID CHROMATOGRAPHY & RELATED TECHNOLOGIES. VOL. 31. ISSUE 1. P. 107 -133 | 28 | 85% | 0 |
9 | PABST, MJ , BERANOVA-GIORGIANNI, S , KRUEGER, JM , (1999) EFFECTS OF MURAMYL PEPTIDES ON MACROPHAGES, MONOKINES, AND SLEEP.NEUROIMMUNOMODULATION. VOL. 6. ISSUE 4. P. 261 -283 | 65 | 45% | 26 |
10 | BASCHANG, G , (1989) MURAMYLPEPTIDES AND LIPOPEPTIDES - STUDIES TOWARDS IMMUNOSTIMULANTS.TETRAHEDRON. VOL. 45. ISSUE 20. P. 6331 -6360 | 63 | 57% | 83 |
Classes with closest relation at Level 1 |